| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PEPT1; HPECT1; HPEPT1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC15A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于SLC15A1抗体的参考文献(示例基于虚构内容，实际文献需通过数据库检索确认)：
1. **"Characterization of a polyclonal antibody for SLC15A1/PEPT1 in human intestinal epithelial cells"**
- **作者**: Smith A, et al.
- **摘要**: 开发并验证了一种针对人SLC15A1的多克隆抗体，通过免疫印迹和免疫组化证实其在肠道上皮细胞中的特异性表达，为研究肽类转运机制提供工具。
2. **"SLC15A1 expression in cancer: A monoclonal antibody-based study"**
- **作者**: Johnson B, et al.
- **摘要**: 利用单克隆抗体分析SLC15A1在多种肿瘤组织中的表达，发现其在结肠癌中高表达且与化疗药物吸收相关，提示其潜在临床意义。
3. **"Localization of SLC15A1 in renal and gastrointestinal tissues using a novel immunohistochemical approach"**
- **作者**: Lee C, et al.
- **摘要**: 通过新型抗体优化免疫组化方法，揭示SLC15A1在小鼠肾脏近端小管和小肠刷状缘膜的特异性分布，支持其在肽类重吸收中的作用。
4. **"Validation of SLC15A1 antibody for functional studies in inflammatory bowel disease models"**
- **作者**: Zhang Y, et al.
- **摘要**: 验证商业SLC15A1抗体在炎症性肠病模型中的适用性，证明其在蛋白质表达下调检测中的可靠性，并关联其表达与肠道屏障功能受损。
(注：以上为模拟示例，实际文献需通过PubMed/Google Scholar等平台以关键词“SLC15A1 antibody”或“PEPT1 antibody”检索。)
The solute carrier family 15 member 1 (SLC15A1), also known as peptide transporter 1 (PepT1), is a proton-coupled oligopeptide transporter primarily expressed in the intestinal epithelium and renal proximal tubules. It facilitates the uptake of di/tripeptides and peptide-like drugs across cell membranes, playing a critical role in nutrient absorption and pharmacokinetics. SLC15A1 antibodies are immunological tools designed to detect and study the expression, localization, and function of this transporter protein.
These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate SLC15A1's tissue distribution, regulatory mechanisms, and involvement in diseases. For example, upregulated SLC15A1 expression has been linked to inflammatory bowel disease (IBD) and certain cancers, where it may influence nutrient uptake in tumor microenvironments or modulate drug responsiveness. Researchers also utilize SLC15A1 antibodies to explore its role in oral drug delivery systems and interactions with therapeutic agents.
Most commercially available SLC15A1 antibodies are raised against specific epitopes of the human protein, often targeting extracellular or intracellular domains. Validation includes testing for specificity in knockout models or siRNA-treated cells. Proper antibody selection is crucial for minimizing cross-reactivity with homologous transporters like SLC15A2 (PepT2). As a key mediator of peptide transport, SLC15A1 remains a focal point in studies of intestinal physiology, disease mechanisms, and drug development.
×
